Satellos Bioscience Inc. (MSCL:TSX) closed at $9.50 on October 14, 2026, down 4.04% on the day. The stock trades 49.9% below its 52-week high of $18.98 and 25.7% above its 52-week low of $7.56. Over the past year, it gained 7.0%. Satellos Bioscience Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -4.04% | -26.98% | -22.70% | -11.22% | +6.98% |
In 252 trading sessions since October 14, 2025, MSCL closed higher on 111 days (44%). Its best day was June 25, 2026 (+21.31%) and its worst was March 10, 2026 (-18.90%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 3 times.
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.
Find more stocks like MSCL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.